Lead with liquid
Lead with Guardant360® CDx

Guideline-complete genomic profiling results

The first FDA-approved comprehensive liquid biopsy

Receive comprehensive genomic results in just 7 days

Guide appropriate treatment for more newly diagnosed NSCLC patients.*

In the NILE study, a prospective, head-to-head study of 282 patients, leading with Guardant360 LDT detected 20% more patients with biomarkers than leading with tissue testing.19

*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.

20% more patients with biomarkers detected using Guardant360 first 20% more patients with biomarkers detected using Guardant360 first

*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.

Inform treatment decisions across all solid tumors

Guardant360 CDx Gene List

View List

You might also be interested in:

Enhance Your Practice with Guardant360 CDx

Make Guardant360 CDx a routine part of care

Learn More

A New Standard of Care

Rebecca Nagy, Vice President of Medical Affairs, discusses how complete genomic profiling has become a standard of care

Read Now

The Importance of FDA Approval when Choosing Liquid Biopsy

The latest webinar from our Peer Education Program

Watch Now